Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 2/20 | 0.52 |
| ▸ | PPARG | P37231 | 1/20 | 0.48 |
| ▸ | CTSS | P25774 | 1/20 | 0.47 |
| ▸ | CASP3 | P42574 | 14/20 | 0.47 |
| ▸ | CASP8 | Q14790 | 11/20 | 0.47 |
| ▸ | CASP6 | P55212 | 9/20 | 0.47 |
| ▸ | KLK7 | P49862 | 1/20 | 0.45 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.45 |
| ▸ | ACE | P12821 | 1/20 | 0.44 |
| ▸ | CASP1 | P29466 | 2/20 | 0.44 |
| ▸ | CASP9 | P55211 | 2/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30220135 | 0.91 | CACNA1B (0.44) | PPARAPPARGCTSSCASP3CASP8 | |
| SCHEMBL30220182 | 0.88 | CTSK (0.44) | PPARAPPARGCTSSCASP3CASP8 | |
| SCHEMBL22390737 | 0.87 | CASP3 (0.49) | CTSSCASP3CASP8CASP6CASP1 | |
| SCHEMBL22390740 | 0.87 | CASP3 (0.49) | CTSSCASP3CASP8CASP6CASP1 | |
| SCHEMBL22404667 | 0.87 | KLK7 (0.47) | PPARACASP3CASP8CASP6KLK7 | |
| SCHEMBL22404745 | 0.86 | KLK7 (0.46) | PPARACTSSCASP3CASP8CASP6 | |
| SCHEMBL22862226 | 0.85 | KLK7 (0.54) | PPARACASP3CASP8CASP6KLK7 | |
| SCHEMBL22404750 | 0.84 | CTSK (0.47) | CTSSCASP3CASP8CASP6 | |
| SCHEMBL22390694 | 0.82 | CASP3 (0.48) | CTSSCASP3CASP8CASP6 | |
| SCHEMBL22390697 | 0.82 | CASP3 (0.48) | CTSSCASP3CASP8CASP6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3935042-B1 | CASPASE INHIBITORS AND METHODS OF USE THEREOF | NOBO MEDICINE INC (KR) | 2024-08-28 | — | — | EP | disclosed |
| US-12071412-B2 | Caspase inhibitors and methods of use thereof | NOBO MEDICINE INC. (KR) | 2024-08-27 | — | — | US | disclosed |
| US-20230250067-A1 | CASPASE INHIBITORS AND METHODS OF USE THEREOF | NOBO MEDICINE INC. (KR) | 2023-08-10 | — | — | US | disclosed |
| US-20230250067-A1 | CASPASE INHIBITORS AND METHODS OF USE THEREOF | NOBO MEDICINE INC. (KR) | 2023-08-10 | — | — | US | disclosed |
| US-11597703-B2 | Caspase inhibitors and methods of use thereof | HISTOGEN, INC. (US) | 2023-03-07 | — | — | US | disclosed |
| US-11597703-B2 | Caspase inhibitors and methods of use thereof | HISTOGEN, INC. (US) | 2023-03-07 | — | — | US | disclosed |
| US-20200283396-A1 | CASPASE INHIBITORS AND METHODS OF USE THEREOF | NOBO MEDICINE INC. (KR) | 2020-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230250067-A1 | CASPASE INHIBITORS AND METHODS OF USE THEREOF | CASP1, CASP3, CASP7 | PPARA 3631/4885PPARG 3105/4885CTSS 66/4885 |
| US-20200283396-A1 | CASPASE INHIBITORS AND METHODS OF USE THEREOF | CASP1, CASP3, CASP7 | PPARA 3631/4885PPARG 3105/4885CTSS 66/4885 |
| US-12071412-B2 | Caspase inhibitors and methods of use thereof | CASP1, CASP3, CASP7 | PPARA 3631/4885PPARG 3105/4885CTSS 66/4885 |
| US-11597703-B2 | Caspase inhibitors and methods of use thereof | CASP1, CASP3, CASP7 | PPARA 3631/4885PPARG 3105/4885CTSS 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.